NxStage Medical (NXTM) Earns Coverage Optimism Rating of 0.14

News stories about NxStage Medical (NASDAQ:NXTM) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 45.2259325218986 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Several research analysts have weighed in on the company. Zacks Investment Research raised NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Northland Securities reissued a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research report on Wednesday, November 8th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research report on Tuesday, October 17th. One analyst has rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $30.25.

NxStage Medical (NXTM) opened at $24.49 on Tuesday. NxStage Medical has a 1 year low of $20.45 and a 1 year high of $30.80. The company has a market capitalization of $1,620.00, a price-to-earnings ratio of -116.62 and a beta of -0.08.

In other news, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $27.50, for a total transaction of $96,250.00. Following the transaction, the senior vice president now owns 15,270 shares of the company’s stock, valued at approximately $419,925. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 10,500 shares of company stock worth $275,030 in the last ninety days. Insiders own 4.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “NxStage Medical (NXTM) Earns Coverage Optimism Rating of 0.14” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/09/nxstage-medical-nxtm-earns-coverage-optimism-rating-of-0-14.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit